Loading
Life sciences · Phase 2 Trial
ClinicalTrials.gov · October 21, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Phase 2 Trial.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Registry record from ClinicalTrials.gov (NCT07400588). This is a study registration, not published results. Lead sponsor: Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics. Recruitment status: COMPLETED. Phase: PHASE2. Study type: INTERVENTIONAL. Enrollment: 58 participants (ACTUAL). Conditions: Obese, Obesity, Obesity Type 2 Diabetes Mellitus, Weight Loss. Interventions: DRUG: Aleniglipron; DRUG: Placebo. Primary outcome measures: Incidence, severity and relationship of AEs/SAEs , Baseline to week 31; Assessment of vital signs , Baseline to week 31; Assessment of laboratory measures , Baseline to week 31; Assessment of Electrocardiograms (ECG) , Baseline to week 31. Brief summary: The purpose of this study is to assess the safety and tolerability of aleniglipron at doses up to 180 mg once daily (QD) in participants with T2DM who are living with obesity (body mass index \[BMI\] ≥ 30 kg/m2) or overweight (BMI ≥ 27 kg/m2).